Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Inhibition of Hepatitis B Virus Replication by a Novel GalNAc-siRNA In Vivo and In Vitro.
ACS Omega
January 2025
Suzhou Hepa Thera Biopharmaceutical Company Limited, Shanghai 200120, China.
Current antiviral therapy for the chronic hepatitis B virus (HBV) has a low clinical cure rate, high administration frequency, and limited efficacy in reducing HBsAg levels, leading to poor patient compliance. Novel agents are required to achieve HBV functional cure, and reduction of HBV antigenemia may enhance the activation of effective and long-lasting host immune control. HT-101 is a siRNA currently in phase I clinical trials with promising prospects for future applications.
View Article and Find Full Text PDFEnhanced hepatitis B virus-specific immunity by combining neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B virus infection.
Hepatology
December 2024
Institut Pasteur-TheraVectys Joint Lab, Institut Pasteur, Université Paris Cité, Paris, France.
Article Synopsis
- Researchers explored how combining DNA vaccination with a potent HBV neutralizing antibody might improve treatment for chronic HBV infections, which are hard to manage due to weak immune responses.
- In a study with mice, treatment with the antibody and a DNA vaccine led to the development of specific immune cells in the liver, enhancing immune recruitment but also indicating T cells became dysfunctional over time.
- While this combination therapy did not fully cure the infection, it showed promise by improving the immune response and providing insights into how the liver tolerates HBV.
The Impact of Virologic Parameters and Liver Fibrosis on Health-Related Quality of Life in Black African Patients with Chronic Hepatitis B: Results from a High Endemic Area.
Clin Exp Gastroenterol
October 2020
Hepatology and Gastroenterology Unit, Yopougon Teaching Hospital, Abidjan, Côte d'Ivoire.
Background: The effects of virologic parameters, liver fibrosis, and treatment on the HRQoL in black African patients with CHB are unknown.
Objective: To determine the magnitude and the effects of hepatitis B e antigen (HBeAg), hepatitis B surface antigenemia (HBs antigenemia), viral load, liver fibrosis and treatment on HRQoL impairment in black African patients with CHB using the SF36 (SF36) and chronic liver disease questionnaires (CLDQ).
Materials And Methods: HRQoL comparison was determined in a case-control study and enrolled 214 patients with CHB (mean age: 42 years, male: 65.
Hepatitis B Testing: Old Tricks for Newborn Players.
Pediatr Infect Dis J
June 2020
From the Department of Paediatric Infection and Immunity, Monash Children's Hospital.
We describe 2 preterm neonates with transient hepatitis B surface (HBs) antigenemia detected after Hepatitis B vaccination. Repeat serology in both cases tested negative for hepatitis B surface antigen, confirming transient HBs antigenemia. The duration of transient HBs antigenemia affirms current literature in the pediatric population.
View Article and Find Full Text PDFImpact of hepatitis B vaccination on HBsAg kinetics, interferon-inducible protein 10 level and recurrence of viremia.
Cytokine
November 2017
Internal Medicine Department - Hepatology Division, Zagazig University, Egypt. Electronic address:
Background And Aims: Persistent HBs antigenemia >1000IU/ml has a possibility of viral reactivation and HCC in 8%, so we investigated the effect of HBV vaccine on HBsAg, IP-10, and recurrence of viremia.
Methods: Group I: inactive carriers(n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 1year after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or3years after DNA disappearance in HBeAg negativepatients (n=60).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!